Droperidol vs OLANZAPINE
Economic: direct costs · acute psychosis
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Findings
What do systematic reviews say?
34 questions · 34 findings · 2 reviews · Schizophrenia
No studies found 2 · 5.9%GRADE not reported 9 · 26.5%Very low 0 · 0%Low 5 · 14.7%Moderate 9 · 26.5%High 9 · 26.5%
Droperidol vs placebo
Adverse effects ‐ cardiovascular ‐ arrhythmia · acute psychosis
Droperidol showed no clear difference in adverse effects ‐ cardiovascular ‐ arrhythmia compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.34 [0.01, 8.31]1 study · 227 participantsModerate
Droperidol vs placebo
Adverse effects ‐ respiratory ‐ airway obstruction · acute psychosis
Droperidol showed no clear difference in adverse effects ‐ respiratory ‐ airway obstruction compared with placebo (low certainty).
1 finding from 1 review
- RR 0.62 [0.15, 2.52]1 study · 227 participantsLow
Droperidol vs placebo
Service use: person able to be discharged home · acute psychosis
Droperidol showed no clear difference in service use: person able to be discharged home compared with placebo (high certainty).
1 finding from 1 review
- RR 1.16 [0.9, 1.48]1 study · 227 participantsHigh
Droperidol vs placebo
Mental state ‐ improvement · acute psychosis
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Droperidol vs placebo
Economic: direct costs · acute psychosis
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Droperidol vs haloperidol
Tranquillisation or asleep · acute psychosis
Droperidol showed no clear difference in tranquillisation or asleep: tranquillised/sleep ‐ by around 30 minutes compared with haloperidol (high certainty).
1 finding from 1 review
- RR 1.01 [0.93, 1.09]1 study · 228 participantsHigh
Droperidol vs haloperidol
Global state: use of additional medication ‐ by 60 minutes after initial adequate sedation until ED discharge (various psychotropic drugs) · acute psychosis
Droperidol leads to lower global state: use of additional medication ‐ by 60 minutes after… compared with haloperidol (high certainty).
1 finding from 1 review
- RR 0.37 [0.16, 0.9]2 studies · 255 participantsHigh
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL
Tranquillisation or asleep ‐ not asleep up to 2 hours · psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in tranquillisation or asleep ‐ not asleep up to 2 hours compared with OTHER ANTIPSYCHOTIC: c. DROPERIDOL (moderate certainty).
1 finding from 1 review
- Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes onlyRR 1.07 [0.44, 2.6]1 study · 228 participantsModerate
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL
Repeated need for rapid tranquillisation ‐ more than 1 injection · psychosis‐induced aggression or agitation
HALOPERIDOL probably leads to higher repeated need for rapid tranquillisation ‐ more than 1 injection compared with OTHER ANTIPSYCHOTIC: c. DROPERIDOL (moderate certainty).
1 finding from 1 review
- Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes onlyRR 2.38 [1.27, 4.47]2 studies · 255 participantsModerate
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL
Specific behaviour ‐ threat or injury to self or others ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
- Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL
Global outcome ‐ need for benzodiazepine during 24 hours · psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in global outcome ‐ need for benzodiazepine compared with OTHER ANTIPSYCHOTIC: c. DROPERIDOL (moderate certainty).
1 finding from 1 review
- Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes onlyRR 0.31 [0.07, 1.44]1 study · 228 participantsModerate
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL
Adverse effects: specific ‐ dystonia · psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in adverse effects: specific ‐ dystonia compared with OTHER ANTIPSYCHOTIC: c. DROPERIDOL (moderate certainty).
1 finding from 1 review
- Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes onlyRR 0.86 [0.11, 6.56]2 studies · 255 participantsModerate
HALOPERIDOL vs OTHER ANTIPSYCHOTIC: c. DROPERIDOL
Economic outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
- Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found